CNTB Stock Analysis: Buy, Sell, or Hold?
CNTB - Connect Biopharma Holdings Limited Ordinary Shares
$2.23
0.08 (3.72%)
▲
5d:
-7.08%
30d:
-10.08%
90d:
-13.9%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CNTB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: CNTB shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $2.23, which is considered oversold relative to its 30-day fair value range of $2.29 to $2.50.
Technical Outlook: Technically, CNTB is showing sideways momentum. Immediate support is located at $2.15, while resistance sits at $2.72. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CNTB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.07 (+217.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CNTB is showing sideways momentum. Immediate support is located at $2.15, while resistance sits at $2.72. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: CNTB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.07 (+217.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.29 -
$2.50
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 217.1% below Wall St target ($7.07)
- CAUTION: Recommendation downgraded due to -7.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$2.29 -
$2.50
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.15
Resistance Level
$2.72
Current Trend
Sideways
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.13
Wall Street Target
$7.07
(+217.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 03, 2026 8:51 PM ET
Data refreshes hourly during market hours. Next update: 9:51 PM
Data refreshes hourly during market hours. Next update: 9:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
James Huang
BUY
1160000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
